NCT06942624 is a Phase 1/Phase 2 clinical trial of Phage Therapy in Periprosthetic Joint Infection, sponsored by Orthopaedic Innovation Centre.

Who is sponsoring NCT06942624?

NCT06942624 is sponsored by Orthopaedic Innovation Centre.

What drugs are being tested in NCT06942624?

Interventions in NCT06942624: Phage Therapy.

What condition does NCT06942624 study?

NCT06942624 studies Periprosthetic Joint Infection.

Is NCT06942624 still recruiting?

NCT06942624 is currently not yet recruiting. Last updated 17 April 2025.

Last reviewed 2025-04-17 · How we verify

NCT06942624

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phage Therapy for the Treatment of a Chronic Enterococcus Faecium Periprosthetic Joint Infection

Not yet recruiting Phase 1/Phase 2 Last updated 17 April 2025

What this trial tests

Phase 1/Phase 2 trial testing Phage Therapy in Periprosthetic Joint Infection in 1 participant. Not yet recruiting.

Timeline

1 May 2025

Primary endpoint
1 June 2026

1 June 2026

Quick facts

Lead sponsor	Orthopaedic Innovation Centre
Phase	Phase 1/Phase 2
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	1
Start date	1 May 2025
Primary completion	1 June 2026
Estimated completion	1 June 2026
Sites	1 location across Canada

Drugs / interventions tested

Phage Therapy — full drug profile →

Conditions studied

Periprosthetic Joint Infection — all drugs for Periprosthetic Joint Infection →

Sponsor

Orthopaedic Innovation Centre

Who can join

18 and older, male only, with Periprosthetic Joint Infection. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Safety of phage therapy
Time frame: Day 0 to 1 year from treatment
Reactions and adverse events to the treatment
Efficacy of phage therapy
Time frame: 1 Year
No recurrence of the infection
Tolerability of phage therapy
Time frame: Day 0 to Day 13 of treatment
Reactions and adverse events to the intravenous and intra-articular administration

Sponsor's own description

This purpose of this clinical trial is to evaluate the safety, tolerability and efficacy of a bacteriophage therapy in a patient with a methicillin-susceptible Enterococcus faecium (E. faecium) prosthetic joint infection (PJI) of the hip. We have exhausted all surgical and medical management of PJI for our patient. The phage will be administered to the study patient during a 14 days period via intravenous and intra-articular. The patient will be monitored in clinic for up to 1 year.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Antimicrobial Resistance: The Answers.
Millar BC, Cates MJ, Torrisi MS, Round AJ, et al · · 2026 · PMID 41727556 · DOI 10.3389/bjbs.2026.15559
Is a Bacteriophage Approach for Musculoskeletal Infection Management an Alternative to Conventional Therapy?
Eschweiler J, Fischer C, Migliorini F, Greven J, et al · · 2025 · PMID 41157207 · DOI 10.3390/life15101534
Bacteriophage-Based Approach Against Biofilm Infections Associated with Medical Devices: A Narrative Review of ESKAPE Pathogens.
Pawłuszkiewicz K, Busłowicz T, Korgiel M, Faltus A, et al · · 2025 · PMID 40943617 · DOI 10.3390/ijms26178699

Verify or expand the search:

Other trials of Phage Therapy

Trials testing the same drug.

NCT05537519 — Phage Therapy for the Treatment of Urinary Tract Infection · Phase 1, PHASE2 · unknown
NCT04636554 — Personalized Phage Treatment in Covid-19 Patients With Bacterial Co-Infections Microbials for Pneumonia or Bacteremia/Se · no longer available

Other recruiting trials for Periprosthetic Joint Infection

Currently open trials in the same condition.

NCT07313215 — Rifampin-combined Antibiotic Therapy for Staphylococcal PJI · NA · recruiting
NCT06464770 — Optimizing Infection Prophylaxis Prior to Shoulder Surgery · NA · recruiting
NCT06268795 — A Diagnostic Test Accuracy Study Comparing Biopsy to Aspiration in Shoulder and Elbow Arthroplasty Revision Surgery (BAS · recruiting
NCT05284318 — Prospective Cohort Study on Antibiotic Course and Efficacy After Two-stage Revision in PJI. · recruiting

Other Orthopaedic Innovation Centre trials

Trials by the same sponsor.

NCT04649424 — COVID-19 Nasal Swab Trial · NA · completed
NCT04541693 — REDAPT Revision Hip System With RSA · NA · active not recruiting
NCT03416946 — Custom Cutting Block Instrument vs Regular Instrumentation Total Knee Replacement (TKR) · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06942624 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Orthopaedic Innovation Centre
Last refreshed: 17 April 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06942624.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing